Feb. 27 at 3:45 AM
$GERN Geron’s pipeline is a single-asset, with clinical trials only focusing on additional indications, and only Method of Use patents remain valid. I estimate these patents have about 10–11 years left after PTE approval. Under these circumstances, I believe the company has no choice but to consider an M&A.
From my knowledge, EU partners are typically announced before launch or within 6 months—12 months at the very latest. For GERN, it has already been about 19 months. While this could be an issue of profit sharing, I believe they might be proceeding while scouting for potential M&A targets, as a partner unrelated to an M&A could devalue the acquisition price.
I also interpreted the fact that they extended the loan drawdown to July this year, despite being able to execute it in Dec 2025, as a plan to only execute it if M&A negotiations fail. Of course, this is all just my personal opinion.
